Bivi stock forecast 2025 biotech-focused ETFs increasing

Biotech-focused ETFs increasing weighting in the company strengthens the "BIVI stock forecast 2025" case for broader investor interest. This kind of passive inflow can steadily lift demand regardless of short-term sentiment shifts. BioVie's cash burn of US$22m is about 66% of its US$33m market capitalisation. That's very high expenditure relative to the company's size, suggesting it is an extremely high risk stock. BioVie faces significant financial challenges as it remains in the R&D phase with no revenue. The strong equity position offers some balance sheet support, but high cash burn and reliance on external financing are concerns. Technical indicators show bearish momentum, and valuation metrics reflect typical pre-revenue biotech risks. Overall, the stock is rated poorly due to these combined factors. Implied volatility remains elevated, illustrating uncertainty but also opportunity for short-term swing trades around catalyst events.